15,449
Participants
Start Date
November 6, 2018
Primary Completion Date
July 7, 2022
Study Completion Date
May 31, 2024
Egg based influenza vaccines
Participants will be randomly allocated to one of three vaccine types in accordance with standard clinical practices for those in the US military. All vaccines are FDA licensed for use in the United States.
Recombinant influenza vaccines
Participants will be randomly allocated to one of three vaccine types in accordance with standard clinical practices for those in the US military. All vaccines are FDA licensed for use in the United States.
Cell-culture based influenza vaccines
Participants will be randomly allocated to one of three vaccine types in accordance with standard clinical practices for those in the US military. All vaccines are FDA licensed for use in the United States.
USU, Bethesda
Walter Reed National Military Medical Center, Bethesda
United States Naval Academy, Annapolis
Naval Medical Center Portsmouth, Portsmouth
Womack Army Medical Center, Fort Bragg
Naval Medical Center San Diego, San Diego
Brooke Army Medical Center, Fort Sam Houston
Lackland Airforce Base, San Antonio
Madigan Army Medical Center, Tacoma
Collaborators (1)
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Food and Drug Administration (FDA)
FED
Defense Health Agency Immunization Healthcare Branch
UNKNOWN
US Department of Defense Armed Forces Health Surveillance Center
FED
Naval Health Research Center
FED
United States Air Force School of Aerospace Medicine
FED
Uniformed Services University of the Health Sciences
FED
Henry M. Jackson Foundation for the Advancement of Military Medicine
OTHER